Innate Pharma SA(IPHA)stock report

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

Finance:
Market Cap:505.8M; Shares Outstanding:78.5M; Short Interest: 0.06%

EPS and Sales:
https://finance.yahoo.com/quote/IPHA/financials?p=IPHA

Date EPS % last year % last quarter
2017.12.31 -0.99 / /
2018.6.30 -0.29 / 70.71%
2018.12.31 0.06 105.62% 120.69%
2019.6.30 0.23 180.77% 283.33%

 

Date Sales % last year % last quarter
2017.12.31 49.12M / /
2018.6.30 25.65M / -47.78%
2018.12.31 105M 113.37% 309.36%
2019.6.30 65.99M 157.24% -37.15%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=IPHA&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/IPHA/institutional-ownership/

no data

Analyst Ratings:
https://www.tipranks.com/stocks/IPHA/price-targe

Leave a Reply